Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0616A · 1 trial · 1 indication
Blood samples will be collected to determine the AUC0-inf of enlicitide in plasma
Blood samples will be collected to determine the AUC0-inf of rosuvastatin in plasma
Blood samples will be collected to determine the AUC0-last of enlicitide in plasma
Blood samples will be collected to determine the AUC0-last of rosuvastatin in plasma
Blood samples will be collected to determine the cmax of enlicitide in plasma
Blood samples will be collected to determine the cmax of rosuvastatin in plasma
| Arm | Type | Description |
|---|---|---|
| Enlicitide + Rosuvastatin Part 1 | EXPERIMENTAL | Participants in Part 1 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet |
| MK-0616A Part 1 | EXPERIMENTAL | Participants in Part 1 will receive a single dose of MK-0616A |
| Enlicitide + Rosuvastatin Part 2 | EXPERIMENTAL | Participants in Part 2 will receive a single dose of enlicitide tablet coadministered with a single dose of rosuvastatin tablet |
| MK-0616A Part 2 | EXPERIMENTAL | Participants in Part 2 will receive a single dose of MK-0616A formulation B |
| Name | Type | Description |
|---|---|---|
| MK-0616A | DRUG | Enlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets |
| Enlicitide | DRUG | Oral tablet |
| Rosuvastatin | DRUG | Oral tablet |
The main inclusion criteria include but are not limited to the following: * Is medically healthy with no clinically significant medical history * Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry Exclusion Criteria: * Is unable t...
MK-0616A is an investigational small molecule being studied in healthy adults. It is currently in Phase 1 clinical development, with an ongoing trial evaluating its effects in healthy volunteers. The drug is not approved and remains under investigation.
MK-0616A is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting a Phase 1 clinical trial of the drug in healthy adults in the United States.
MK-0616A is in Phase 1 clinical development. It is an investigational drug and has not been approved. A Phase 1 trial is currently recruiting participants to study the drug in healthy adults.
MK-0616A is being studied in a Phase 1 clinical trial with the identifier NCT07300280. The trial, titled "A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)," is recruiting 60 healthy participants in the United States.
MK-0616A is associated with the drug enlicitide, as indicated by the clinical trial title. The trial NCT07300280 evaluates enlicitide and rosuvastatin in healthy adults, and MK-0616A is the compound identifier used in the study.